Clariane


Integrating the above-expectation mid-term guidance

06/06/24 -"We have incorporated the latest financial guidance, which was largely above our previous forecasts, resulting in a significant boost to our target price. Please note that the significant imbalance ..."

Pages
69
Language
English
Published on
06/06/24
You may also be interested by these reports :
24/06/24
A year ago, we suggested Healthineers (Reduce, Germany) as a potential investment. Since then, our projected upside has halved, leading us to ...

19/06/24
Taking into consideration the management’s recent guidance downgrade due to the ongoing weakness in China and delay in interest rate cuts in the US, ...

18/06/24
Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer ...

13/06/24
The group has completed the first tranche of its planned recap and will launch the second one, with a deep discount (65% on the closing price as of ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO